Clinical Trial Update: TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial of the agent TKI258 in subjects with refractory or relapsed multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TKI258

Snippet

Sponsor: Novartis | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED